Editorial Central & Peripheral Nervous Systems: Dopamine D₁ receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease

Abstract

While early experience with D₁ receptor agonists in Parkinson's disease (PD) was disappointing, more recent work, especially in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys, has shown that D₁ selective receptor agonists and dopamine reuptake blockers (themselves likely to influence motor systems predominantly through D₁-mediated mechanisms), have powerful antiparkinsonian effects and may also effectively combat common complications of current treatment, such as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias.